Levels of Circulating Cell-Free Nuclear and Mitochondrial DNA in Benign and Malignant Ovarian Tumors
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To analyze the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in patients with benign and malignant ovarian tumors using a gold-standard assay and to investigate whether quantitative alterations of the circulating cell-free species have values in the management of the patients. METHODS: One hundred four patients were recruited for this study. We developed a quantitative, multiplex polymerase chain reaction to measure the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in serum and plasma of patients with epithelial ovarian cancer, benign epithelial ovarian tumors, or endometriosis. The levels of the circulating cell-free DNA were compared with those of a healthy, age-matched control group. RESULTS: The patients with epithelial ovarian cancer had significantly higher amounts of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in plasma compared with the healthy control group (mean of nuclear DNA 10,723/2,591 and mean of mitochondrial DNA 4,918,978/2,294,264, P=.009 and 0.022, respectively) and with the other group with benign ovarian diseases (mean of nuclear DNA 10,723/2,965 and mean of mitochondrial DNA 4,918,978/1,597,551, P=.027 and 0.002, respectively). However, no relationship between levels of the circulating cell-free DNA and the pathological parameters as well as CA 125 measurement in patients with epithelial ovarian cancer was found. A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA (mean of mitochondrial DNA 4,918,978/2,273,988 and mean of nuclear DNA 10,723/3,291, P=.013 and 0.105, respectively). CONCLUSION: Elevated levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in epithelial ovarian cancer may have diagnostic value. Our finding suggests that the circulating molecules might be potential biomarkers in the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, circulating mtDNA has been identified in patients with ovarian (Zachariah et al., 2008), testicular (Ellinger et al., 2009), prostate (Ellinger et al., 2009), and lung cancer (Hou et al., 2013).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Zachariah et al., 2008
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Lo, Y. M. D., Tein, M. S. C., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M. K., Wainscoat, J. S., Johnson, P. J., Chang, A. M. Z., & Hjelm, N. M. (1998) · The American Journal of Human Genetics · doi:10.1086/301800 · Cited by 1,653
Rapid Clearance of Fetal DNA from Maternal Plasma
Lo, Y. M. D., Zhang, J., Leung, T. N., Lau, T. K., Chang, A. M. Z., & Hjelm, N. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302205 · Cited by 1,157
Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer
Sozzi, G., Conte, D., Leon, M., Cirincione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.006 · Cited by 552
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Zhong, X. Y., Laivuori, H., Livingston, J. C., Ylikorkala, O., Sibai, B. M., Holzgreve, W., & Hahn, S. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.109594 · Cited by 284
Self-citationMalkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., Mortel, R., Berek, J. S., Bast, R. C., & Ritts, R. E. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80081-4 · Cited by 227
Quantitative Analysis of Circulating Mitochondrial DNA in Plasma
Chiu, R. W. K., Chan, L. Y. S., Lam, N. Y. L., Tsui, N. B. Y., Ng, E. K. O., Rainer, T. H., & Lo, Y. M. D. (2003) · Clinical Chemistry · doi:10.1373/49.5.719 · Cited by 208
Cited by
Items 101–142 of 142
The level of blood plasma mitochondrial DNA upon acute myocardium damage in experiment
Sudakov, N. P., Popkova, T. P., Новикова, М. А., Katyshev, A. I., Nikiforov, S. B., Пушкарев, Б. Г., Гольдберг, О. А., Klimenkov, I., Lepekhova, S. A., Дмитриевна, Е. С., et al. (2012) · Biopolymers and Cell · doi:10.7124/bc.00006b · Cited by 6
Cell-free nucleic acids in urine as potential biomarkers of kidney disease
Gyurászová, M., Kovalčíková, A. G., Bábíčková, J., Hodosy, J., & Tóthová, Ľ. (2018) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2018.01.007 · Cited by 6
“Patients suffering from age-related neurodegenerative disorders have shown that mtDNAs in human plasma exist as [21_TD$DIFF]the particleassociated and free state. mtDNA has also been described in exosomes and in relation to neutrophils (Mehra et al., 2007; Tsai et al., 2011; Zachariah et al., 2008).”
BackgroundYanev, N., Mekov, E., Valev, D., Yankov, G. S., Milanov, V., Bichev, S., Gabrovska, N., & Kostadinov, D. (2021) · PeerJ · doi:10.7717/peerj.11448 · Cited by 6
“However, it requires the use of more sensitive diagnostic methods due to the very small amount of ctDNA in plasma (Zachariah et al., 2008; Zanetti-Dallenbach et al., 2007).”
MethodRajaram, S., Varma, A., Gupta, B., Kar, R., Arora, V. K., Jain, S., & Singh, L. (2024) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2024.100022 · Cited by 5
Gunderson, C. C., Radhakrishnan, R., Gomathinayagam, R., Husain, S., Aravindan, S., Moore, K. M., Dhanasekaran, D. N., & Jayaraman, M. (2022) · Biomarker Insights · doi:10.1177/11772719221088404 · Cited by 5
Mitochondrial Cation Signalling in the Control of Inflammatory Processes
Pain, P., Spinelli, F. R., & Gherardi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316724 · Cited by 7
“Also, elevated levels of mtDNA in plasma usually correspond to decreased survival and serve as potential biomarkers for prognosis [115,116].”
BackgroundFu, X., & Liu, Y. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-2609 · Cited by 4
“In this paper, a systematic meta-analysis of the 19 included articles (7-25) was carried out to comprehensively evaluate the diagnostic test that uses histopathological examination as a reference standard to study the diagnostic accuracy of EOC.”
MethodRetractedGruenbaum, B. F., Boyko, M., Delgado, B., Douvdevani, A., Gruenbaum, S. E., Melamed, I., Gideon, M., Cesnulis, E., Shapira, Y., & Zlotnik, A. A. (2012) · Hepatology International · doi:10.1007/s12072-012-9414-z · Cited by 5
“CFD has been found to be a useful biomarker in various conditions such as cancer [28–31], myocardial infarction [15, 32], preeclampsia [33], and prenatal diagnosis [34].”
BackgroundBioenergetics of Human Cancer Cells and Normal Cells during Proliferation and Differentiation
Mikirova, N. A. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/17113 · Cited by 4
“These include increases in, and alteration of, mitochondrial DNA [8,10-14, 20-21], elevation of hexokinase production [15], lysis of cristae structures [23-26] and altered mitochondrial protein and lipid content [24-26].”
BackgroundBioenergetics of Human Cancer Cells and Normal Cells During Proliferation and Differentiation
González, M. J. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.03.555623 · Cited by 4
“Ellinger J, Albers P, Muller SC, von Ruecker A, Bastian PJ (2009) Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel non-invasive diagnostic biomarker.”
BackgroundInfluentialState of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA
Heliebi, A. E., & Heitzer, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00005-8 · Cited by 5
Increase in Circulating MicroRNA Levels in Blood of Ovarian Cancer Patients
Roth, C., Kasimir‐Bauer, S., Heubner, M. L., Pantel, K., & Schwarzenbach, H. (2010) · Springer eBooks · doi:10.1007/978-90-481-9382-0_9 · Cited by 5
Maggiore, U. L. R., Vignali, M., Kvaskoff, M., Chiappa, V., Somigliana, E., Vercellini, P., Raspagliesi, F., & Viganò, P. (2026) · Human Reproduction Update · doi:10.1093/humupd/dmag011 · Cited by 5
Mitochondrial DNA Copy Number Alterations in Human Cancers
Yu, M. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0024873 · Cited by 3
Complexities and pitfalls in analyzing and interpreting mitochondrial DNA content in human cancer
Nguyen, H. T. M., & LaFramboise, T. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.04.007 · Cited by 2
Mitochondrial Genome Changes as Cancer Biomarkers in Circulation
Dakubo, G. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-01580-4_7 · Cited by 1
Ovarian Cancer Biomarkers in Circulation
Dakubo, G. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-48360-3_13 · Cited by 1
Fader, K. A., Gosink, M. M., Xia, S., Lanz, T. A., Halsey, C., Vaidya, V. S., & Radi, Z. A. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116582 · Cited by 1
Girolimetti, G., Guerra, F., Eusebi, L. H., Ricci, C., Marzetti, E., Picca, A., & Bucci, C. (2025) · Applied Sciences · doi:10.3390/app15084410 · Cited by 1
Dakubo, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-11416-8_11
Evaluation of the cell-free mitochondrial DNA quantity in plasma as an aging biomarker candidate
Nevalainen, T. (2012) · Tampere University Institutional Repository (Tampere University) · Cited by 1
Another Ovarian Cancer Marker — Almost There?
Carson, S. A. (2008) · Journal watch · doi:10.1056/wh200811200000003
Sudakov, N. P., Popkova, T. P., Katyshev, A. I., Гольдберг, О. А., & Новикова, М. А. (2013) · CyberLeninK (CyberLeninka)
Prediction of ovarian malignancy using plasma cell-free DNA
El-Garf, W., Elshair, H., Aref, A., Salama, S. H., Gebril, M., Mohesen, M. N., Sayed, M. A., Mahmoud, A. M., Taha, T., Bibers, M., et al. (2015) · Medical Research Journal · doi:10.1097/01.mjx.0000464333.22480.a3
Estado actual de las aplicaciones del ADN libre de célula circulante
Jaraba-Álvarez, W. V., Torres, I. P., Hernández, R. D. M., & Gallo-Bonilla, J. E. (2017) · Medicina y Laboratorio · doi:10.36384/01232576.6
“La elevación del ADN libre de célula en plasma ha sido documentada o reportada en los casos de variación en los niveles de metilación o mutaciones puntuales para el cáncer de seno [42-45], colorrectal [20,4651], de pulmón [52-59] y de próstata [6066], los tumores cervicales [53,67-69], ováricos [70], de esófago [71,72…”
Mitroshina, I. Y., Sirota, N. P., Prokofiev, V. N., & Kuznetsova, E. (2021) · BIOPHYSICS · doi:10.1134/s0006350921020147
Is the Cell-Free Circulating Mitochondrial DNA a Potential Biomarker for Atrial Fibrillation?
Rahmanian, M., Khaheshi, I., Khani, M. M., Bayati, R., Ataee, M., & Sohrabifar, N. (2023) · International Journal of Cardiovascular Practice · doi:10.5812/intjcardiovascpract-141066
“malignancy (27-36), indicating severe cellular stress that results in severe cellular death as an essential factor in the release of mtDNA (37).”
Vijayashanti, T., Rema, P., Lakshmi, S., Sambasivan, S., Ranjith, J. S., Mathew, A., & Krishna, K. M. J. (2024) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-024-00807-y
“…of both cell-free nuclear and mitochondrial DNA among patients of ovarian carcinoma compared to controls, but levels of cell-free DNA did not correlate with prognosis in their cohort. cfDNA levels were significantly raised in stage III and IV ovarian carcinoma compared with stages I and II [18].”
ECM-Lamin Crosstalk in the Regulation of Genomic Stability
Mandal, B., Banerjee, I., Hazari, M. W. A. D., Mondal, A., & Das, C. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-032-00537-3_7 · Cited by 1
Integrated DNA examination with fluorescent biomarker analysis
Czarnomska, M., Gruszczyńska, E., Koczur, J., Laudadio, E., Malinowska, M., & Lewkowicz, A. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.127648
Etude de nouveaux marqueurs moléculaires pour le diagnostic précoce et le pronostic des cancers
Feng, G. (2010) · theses.fr (ABES) · doi:10.70675/90503913z5b58z4aa8za556z2ca16a75723d
ADN circulant nucléaire et mitochondrial et étude de l'influence de l'hypoxie sur leur libération
Cherone, A. (2019) · theses.fr (ABES) · doi:10.70675/35b2e61fz1d02z485cz8e73zce1599d078b8
Musicco, C., Signorile, A., Rasmo, D. D., Loizzi, V., Cormio, G., & Cormio, A. (2026) · Biomolecules · doi:10.3390/biom16060771
“CfmtDNA levels were quantified by qRT-PCR in serum and plasma samples obtained from 24 patients with benign ovarian tumors, 21 patients with epithelial ovarian cancer (EOC), 23 patients with endometriosis, and 36 age-matched healthy controls [60].”
Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy
Elgedawy, G. A., Adbelmoneum, R. A., Aldesoky, A. I., Mashal, S. S., Awad, A. E., Elabd, N. S., & Helal, M. (2026) · BMC Cancer · doi:10.1186/s12885-026-15967-7
“In comparison with controls, Zachariah and colleagues found that ovarian cancer patients had higher levels of both cell-free nuclear and mitochondrial DNA; however, their cohort’s prognosis was not correlated with cfDNA levels [27].”
Metadata
- Authors
- Zachariah, R. R., Schmid, S., Buerki, N., Radpour, R., Holzgreve, W., & Zhong, X.
- Affiliations
- University of Basel (CH)
- Venue
- Obstetrics & Gynecology
- Published
- 2008-10
- Volume
- 112
- Issue
- 4
- Pages
- 843-850
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2076316408
- Cited by
- 142
- References
- 25
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 10 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 8 · 2012: 11
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- cell-free DNA, cell-free mitochondrial DNA, epithelial ovarian cancer, benign ovarian tumors, endometriosis, liquid biopsy, tumor markers, CA125
- MeSH terms
- Adult, Cell-Free System, DNA, Mitochondrial, DNA, Neoplasm, Endometriosis, Female, Humans, Ovarian Neoplasms, ROC Curve, Biomarkers, Tumor, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.